Louvain-La-Neuve, Belgium, January 27, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract for the supply of a Proteus®ONE1 compact proton therapy solution to be installed at the MacKay Memorial Hospital in New Taipei City, Taiwan. This is the fourth order of a Proteus®ONE system in Taiwan, further reinforcing IBA’s position as ...

Company Overview - IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology and the leading supplier of proton therapy solutions for cancer treatment [5][6] - The company employs approximately 2,100 people globally and is based in Louvain-la-Neuve, Belgium [5] - IBA is listed on the EURONEXT stock exchange and is a certified B Corporation, meeting high standards of social and environmental performance [5][6] Contract Details - IBA has signed a contract with Seoul St. Mary's Hospital for the installation of a ProteusPLUS solution, which includes three gantry-rooms and a multi-year service contract [2][3] - The system will feature DynamicARC beam delivery capabilities once it receives regulatory clearance [2] - The hospital plans to begin patient treatments by the end of 2029, with the center covering a total area of 37,851 square meters [2] Market Impact - The contract signifies the growing demand for proton therapy solutions in South Korea, expanding the number of centers that utilize IBA's technology [3] - The typical end-user price for a three-room ProteusPLUS system with a multi-year maintenance contract ranges between €80 million and €100 million [3] Hospital Profile - Seoul St. Mary's Hospital is one of the largest hospitals in South Korea and a flagship institution of the Catholic Medical Center, providing comprehensive care across 45 departments [6] - The hospital has a global reputation for treating blood cancers and is also expanding its capabilities in treating solid tumors [3][6] - It has treated over 30,000 international patients from more than 100 countries and has trained over 900 international physicians through its fellowship programs [6]